Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
36 participants
INTERVENTIONAL
2019-11-26
2021-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective: The primary objectives are: 1) to further investigate the effect of CA on semantic processing. The study plans to examine whether MPH interacts with processing of sentence context constraints via its influence on cognitive control operations. 2) To investigate the effects of MPH on syntactic processing. More specifically, the study is interested in whether MPH has an influence on revising syntactically temporarily ambiguous sentences.
A secondary objective is to further examine the relation between MPH effects and the baseline characteristics of individual participants.
Study design: This study will use a within-subject, double-blind, placebo-controlled, randomized, crossover design.
Study population: Approximately 40 healthy native Dutch speakers between 18 and 45 years old will be recruited. All subjects will have to complete one screening session and two separate testing sessions within three different days at the Donders Centre for Cognitive Neuroimaging (DCCN).
Intervention: Participants will either orally receive a 20mg methylphenidate or placebo capsule in each of the two testing sessions. Methylphenidate has been approved for clinical use in the Netherlands and the drug can be administered safely without any relevant risk of serious adverse events.
Main study parameters: Primary study parameters will include sentence comprehension capacity, attention and processing speed. In addition, several other measures will be included to monitor participants' baseline characteristics (e.g. working memory capacity, vocabulary size) and the general modulation effects of MPH (e.g. heart rate, blood pressure, subjective feeling).
Hypotheses:
Based on the previous finding that methylphenidate improves cognitive stability while it impairs flexible updating, the hypothesis is that methylphenidate will hinder participants' performance in resolving syntactic ambiguity, which requires an immediate updating and revising of an initial interpretation. This should be reflected in event-related potential (ERP) measures related to revision, namely the P600 effect is predicted to be reduced in the drug condition compared to placebo.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
NCT02247986
Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study
NCT02326038
Dopaminergic Modulation of Cognition and Psychomotor Function
NCT01218425
Large-scale Brain Organization During Cognitive Control in ADHD
NCT04349917
Neuroimaging of the Effects of Concerta in the Treatment of ADHD
NCT00778310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug Session
In this arm of the study participants receive the drug (Methylphenidate - 20mg), administered prior to completion of the primary and secondary tasks for the study.
Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized.
Methylphenidate 20 Mg Oral Tablet
20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
Language Task
The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
Rest Recording
Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
Go/No-Go Task
A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
Processing Speed
A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
Placebo Session
In this arm of the study participants receive the a placebo, administered prior to completion of the primary and secondary tasks for the study.
Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized.
Placebo
20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
Language Task
The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
Rest Recording
Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
Go/No-Go Task
A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
Processing Speed
A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
Intake Session
In this arm of the study participants are screened for suitability to participate in the experiment based on specified inclusion and exclusion criteria. They also complete some baseline tasks to assess working memory capacity, impulsiveness, and subjective mood.
Operation Span
In the operation span task, participants are instructed to solve math operations (e.g., (1\*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
Reading Span
Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
Barratt Impulsiveness Scale
The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylphenidate 20 Mg Oral Tablet
20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
Placebo
20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
Language Task
The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
Rest Recording
Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
Go/No-Go Task
A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
Processing Speed
A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
Operation Span
In the operation span task, participants are instructed to solve math operations (e.g., (1\*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
Reading Span
Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
Barratt Impulsiveness Scale
The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right-handed
Exclusion Criteria
* Current (or history of) neurological disorder (e.g. m. Parkinson, epilepsy)
* Current (or history of) endocrine / metabolic disorder
* Current (or history of) cardiac or vascular disorder
* Current (or history of) blood illness (e.g. severe anaemia, porphyria)
* Current (or history of) stomach or gastrointestinal tract disease
* History of autonomic failure (e.g., vasovagal reflex syncope)
* Experience of irregular sleep-wake rhythm
* Current (or history of) obstructive respiratory disease
* Current (or history of) clinically significant renal or hepatic disease
* (Recent treatment of) glaucoma
* Current (or history of) drug addiction (e.g. opiate, (meth)amphetamine, lysergic acid diethylamide, cocaine, solvents or barbiturate) or alcohol dependence
* One first degree or two or more second degree family members with a recent treatment of sudden death or ventricular arrhythmia
* Problems swallowing or problems with the oesophagus
* Frequent experience of headrush (vertigo)
* Current experience of an acute serious infection
* First degree family member with schizophrenia or bipolar disorder
* Abnormal hearing or (uncorrected) vision
* Use of psychotropic medication or recreational drugs weekly or more over a period of more than three months in the last 6 months
* Cannabis usage for the last 6 months
* Strong smoking behaviour starting at more than 1 package of cigarettes per week
* Hypersensitivity for e.g. beta blockers or methylphenidate
* Uncontrolled hypertension, defined as diastolic blood pressure at rest \>95 mmHg or systolic blood pressure at rest \>180 mmHg
* Irregular sleep/wake rhythm (e.g. regular nightshifts or cross timeline travel)
* Possible pregnancy or breastfeeding/ inadequate anticonception (for women)
* Lactose intolerance (because the placebo pill will be a lactose product)
* Language related disabilities (e.g. dyslexia, stuttering)
* Daily intense physical training
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Max Planck Institute for Psycholinguistics
UNKNOWN
Radboud University Medical Center
OTHER
Donders Centre for Cognitive Neuroimaging
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Hagoort, PhD
Role: PRINCIPAL_INVESTIGATOR
Donders Centre for Cognitive Neuroimaging
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Donders Institute for Brain, Cognition and Behaviour, Centre for Cognitive Neuroimaging
Nijmegen, Gelderland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL69700.091.19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.